Shares in Summit Therapeutics (LON:SUMM) shot up 90% after it confirmed it had signed a licensing deal with the US biotech Sarepta Therapeutics (NASDAQ:SRPT) worth up to US$522mln.
The pair will collaborate on Summit’s potentially breakthrough treatment for Duchenne muscular dystrophy (DMD), a muscle wasting disease that affects boys.
Venn Life Sciences Holdings (LON:VENN) is planning to hive off its skin sciences business on what is expected to become a separate AIM company.
As part of the transaction, Venn and Cayman-domiciled Helium Rising Stars Fund are selling Innovenn to a firm called Integumen.
Tethyan Resources PLC (LON:TETH) announced that Tim Coughlin has resigned as a director to pursue other activities.
Balkans quarry group Fox Marble PLC (LON:FOX) is at the centre of a new US-backed initiative to establish a major quarry industry in Kosovo.
Stone Alliance, a company 59% owned by the AIM-listed group, is proposing to raise €100mln to establish a network of 40 quarries.
Metal Tiger PLC (LON:MTR) reported high copper recovery rates from initial testwork on ore from its T3 prospect in Botswana.
The prospect, which is 30% owned by Metal Tiger and 70% by Aussie-listed MOD Resources, said concentrates of at copper grades between 33% and 60.6% were possible based on the recoveries so far.
Empyrean Energy Plc (LON:EME) is to pay out £17.5mln of cash to its shareholders.
The company revealed it will out 7.9p per share to shareholders.
It will be transacted through the issue of newly created B shares, worth 7.9p each, which will be redeemed from shareholders by the company for cash.
Europa Oil & Gas Holdings Plc (LON:EOG) has confirmed a reassignment of interests in PEDL299, which host the Hardstoft oil field.
The company previously acquired an additional 16.665% interest in the asset from Shale Petroleum Limited, paying a nominal £1. That stake is now being split with fellow partner Upland Resources.
Late clinical-stage cancer therapy group Nanobiotix (EPA:NANO) has strengthened its US leadership team.
The group has appointed Dr Mihail Obrocea as the head of US clinical development and Noёl Kurdi as the director of investor relations.